At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 424 enrolled
Drug / intervention
insulin degludec/insulin aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL)
In Brief
A Phase 3 clinical trial evaluating insulin degludec/insulin aspart and biphasic insulin aspart 30 for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 424 participants across 46 sites in 5 countries.
Detailed Summary
This trial is conducted in Asia. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with biphasic insulin aspart (BIAsp) 30 in patients with type 2 diabetes not optimally controlled on once or twice daily insulin with or without metformin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesHong Kong, Japan, Malaysia, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartFeb 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedFeb 1, 2010
Enrollment StartFeb 1, 2010
Primary CompletionDec 23, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.4 years ago
Interventions
insulin degludec/insulin aspartdrug
Injected subcutaneously twice daily. Dose was individually adjusted.
biphasic insulin aspart 30drug
Injected subcutaneously twice daily. Dose was individually adjusted.